Fluoxetine improves the quality of life in patients with poststroke emotional disturbances

Cerebrovascular Diseases

Volumn 26, Issue 3, 2008, Pages 266-271

  Choi Kwon, S ^a   Choi, J ^a   Kwon, S U ^b   Kang, D W ^b   Kim, J S ^b,c  

^a Seoul National University   (South Korea)

^b University of Ulsan   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

Depression; Emotion; Fluoxetine; Quality of life

Indexed keywords

FLUOXETINE; PLACEBO;

ADULT; ANGER; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DRUG EFFICACY; EMOTIONAL DISORDER; EMOTIONAL INCONTINENCE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SOCIAL INTERACTION; STROKE; STROKE PATIENT;

AFFECTIVE SYMPTOMS; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 47549087802     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000147454     Document Type: Article

References (42)

1. Kim JS, Choi-Kwon S: Poststroke depression and emotional incontinence: correlation with lesion location. Neurology 2000;54:1805-1810.
2. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier T, Newman RM, Curdue K, Petracca G, Starkstein SE: Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000;57:351-359.
3. Robinson RG: Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003;54:376-387.
4. Gabaldon L, Fuentes B, Frank-Garcia A, Diez-Tejedor E: Poststroke depression: importance of its detection and treatment. Cerebrovasc Dis 2007;24(suppl 1):181-188.
5. Kim JS: Pathologic laughter after unilateral stroke. J Neurol Sci 1997;148:121-125.
6. Tang WK, Chan SSM, Chiu HFK, Ungvari GS, Wong KS, Kwok TCY, Wong KT, Richards PS, Ahuja AT: Emotional incontinence in Chinese stroke patients: diagnosis, frequency, and clinical and radiological correlates. J Neurol 2004;251:865-869.
7. Davidson R, Putnam KM, Larson CL: Dysfunction in the neural circuitry of emotion regulation - a possible prelude to violence. Science 2000;289:591-594.
8. Kim JS, Choi-Kwon S, Kwon SU, Seo YS: Inability to control anger or aggression after stroke. Neurology 2002;58:1106-1108.
9. Kauhanen M, Korpelainen JT, Hiltunen P, Brusin E, Mononen H, Maatta R, Nieminen P, Sotaniemi KA, Myllyla VV: Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke 1999;30:1875-1880.
10. Van de Weg FB, Kuik DJ, Lankhorst GJ: Post-stroke depression and functional outcome: a cohort study investigating the influence of depression on functional recovery from stroke. Clin Rehabil 1999;13:268-272.
11. King RB: Quality of life after stroke. Stroke 1996;27:1467-1472.
12. Kim JS, Choi-Kwon S: Sensory sequelae of medullary infarction: differences between lateral and medial medullary syndrome. Stroke 1999;30:2697-2703.
13. Jonsson A, Lindgren I, Hallstrom B, Norrving B, Lindgren A: Determinants of quality of life in stroke survivors and their informal caregivers. Stroke 2005;36:803-808.
14. Kim JS, Choi-Kwon S, Kwon SU, Lee HJ, Park KA, Seo YS: Factors affecting the quality of life after ischemic stroke: young versus old patients. J Clin Neurol 2005;1:59-68.
15. Aprile I, Piazzini DB, Bertolini C, Caliandro P, Pazzaglia C, Tonali P, Padua L: Predictive variables on disability and quality of life in stroke outpatients undergoing rehabilitation. Neurol Sci 2006;27:40-46.
16. Morris PLP, Robinson RG, Andrzejewski P, Samuels J, Price TR: Association of depression with 10-year poststroke mortality. Am J Psychiatry 1993;150:124-129.
17. Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS: Fluoxetine treatment in post-stroke depression, emotional incontinence and anger-proneness: a double-blind placebo-controlled study. Stroke 2006;37:156-161.
18. Studenski S, Duncan PW, Perera S, Reker D, Lai SM, Richards L: Daily functioning and quality of life in a randomized controlled trial of therapeutic exercise for subacute stroke survivors. Stroke 2005;36:1764-1770.
19. Dettmers C, Teske U, Hamzei F, Uswatte G, Taub E, Weiller C: Distributed form of constraint-induced movement therapy improves functional outcome and quality of life after stroke. Arch Phys Med Rehabil 2005;86:204-209.
20. Tibaek S, Jensen R, Lindskov G, Jensen M: Can quality of life be improved by pelvic floor muscle training in women with urinary incontinence after ischemic stroke? A randomised, controlled and blinded study. Int Urogynecol J Pelvic Floor Dysfunct 2004;15:117-123.
21. Folstein MF, Folstein SE, McHugh PR: 'Minimental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). Med Care 1992;30:473-481.
23. Nam BH, Lee SW: Testing the validity of the Korean SF-36 health survey. J Korean Soc Health Stat 2003;28:3-24.
24. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS: Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovasc Dis 2006;23;103-108.
25. Spilberger CD, Jacobs G, Russell S, Crane RS: Assessment of anger: the State-Trait Anger-Scale; in Butcher JN, Spielberger CD (eds): Advances in Personality Assessment, vol.2. Hillsdale, Erlbaum Associates, 1983, pp 161-189.
26. Choi-Kwon S, Choi JM, Kwon SU, Kang DH, Kim JS: Factors that affect the quality of life at 3 years post-stroke. J Clin Neurol 2006;2:34-41.
27. Suenkeler ICH, Nowak M, Misselwitz B, Kugler C, Schreiber W, Oertel WH, Back T: Timecourse of health-related quality of life as determined 3, 6 and 12 months after stroke - relationship to neurological deficit, disability and depression. J Neurol 2002;249:1160-1167.
28. Choi-Kwon S, Kim HS, Kwon SU, Kim JS: Factors affecting the burden on caregivers of stroke survivors in South Korea. Arch Physic Med Rehabil 2005;86:1043-1048.
29. Kocsis JH, Schatzberg A, Rush AJ, Klein DN, Howland R, Gniwesch L, Davis SM, Harrison W: Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs. placebo. Arch Gen Psychiatry 2002;59:723-728.
30. Stahl SM: Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Clin Psychiatry 2000;48:894-901.
31. Cohen LS, Miner C, Brown E, et al: Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerizes diaries. Obstet Gynecol 2002;100:435-444.
32. Miner C, Brown E, McCray S, et al: Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002;24:417-433.
33. Vitiello B, Rohde P, Silva S, Wells K, Casat C, Waslick B, Simons A, Reinecke M, Weller E, Kratochvil C, Walkup H, Pathak S, Robins M, March J: Functioning and quality of life in the treatment for adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45:1419-1426.
34. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809.
35. Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.
36. Nibuya M, Morinobu S, Duman RS: Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995;15:7539-7547.
37. Dam M, Tonin A, De Boni G, Pizzolato S, Casson M, Ermani U, Frco L, Piron L: Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27:1211-1214.
38. Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F: Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001;50:718-729.
39. Pearlstein TB, Halbreich U, Batzar ED, et al: Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101-109.
40. Halbreich U, Bergeron R, Yonkers KA, et al: Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1213-1229.
41. Windle V, Corbett D: Fluoxetine and recovery of motor function after focal ischemia in rats. Brain Res 2005;1044:25-32.
42. Jolkkonen J, Puurunen K, Rantakomi S, Sirvio J, Haapalinna A, Sivenius J: Effects of fluoxetine on sensorimotor and spatial learning deficits following focal cerebral ischemia in rats. Restor Neurol Neurosci 2000;17:211-216.